- Home
- LOGC vs PLRX Comparison
LOGC vs PLRX Comparison
Compare LOGC & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LOGC
- PLRX
- Stock Information
- Founded
- LOGC 2010
- PLRX 2015
- Country
- LOGC United States
- PLRX United States
- Employees
- LOGC N/A
- PLRX N/A
- Industry
- LOGC Catalog/Specialty Distribution
- PLRX Biotechnology: Pharmaceutical Preparations
- Sector
- LOGC Consumer Discretionary
- PLRX Health Care
- Exchange
- LOGC Nasdaq
- PLRX Nasdaq
- Market Cap
- LOGC 186.8M
- PLRX 165.5M
- IPO Year
- LOGC 2020
- PLRX 2020
- Fundamental
- Price
- LOGC $6.95
- PLRX $1.47
- Analyst Decision
- LOGC
- PLRX Hold
- Analyst Count
- LOGC 0
- PLRX 10
- Target Price
- LOGC N/A
- PLRX $9.79
- AVG Volume (30 Days)
- LOGC 366.4K
- PLRX 3.4M
- Earning Date
- LOGC 03-12-2025
- PLRX 03-03-2025
- Dividend Yield
- LOGC N/A
- PLRX N/A
- EPS Growth
- LOGC N/A
- PLRX N/A
- EPS
- LOGC N/A
- PLRX N/A
- Revenue
- LOGC $43,000,000.00
- PLRX N/A
- Revenue This Year
- LOGC $433.37
- PLRX N/A
- Revenue Next Year
- LOGC N/A
- PLRX $46.66
- P/E Ratio
- LOGC N/A
- PLRX N/A
- Revenue Growth
- LOGC N/A
- PLRX N/A
- 52 Week Low
- LOGC $4.69
- PLRX $1.26
- 52 Week High
- LOGC $9.34
- PLRX $16.52
- Technical
- Relative Strength Index (RSI)
- LOGC 38.65
- PLRX 26.84
- Support Level
- LOGC $7.36
- PLRX $1.42
- Resistance Level
- LOGC $7.73
- PLRX $1.78
- Average True Range (ATR)
- LOGC 0.29
- PLRX 0.13
- MACD
- LOGC -0.05
- PLRX 0.26
- Stochastic Oscillator
- LOGC 27.78
- PLRX 14.08
About LOGC ContextLogic Inc.
ContextLogic Inc is an online shopping store. The store provides personalized products, clothing products, accessories, gaming products and equipment, cosmetics, plastic products, mobile covers, and other products. Geographically, it derives majority of its revenue from Europe and also has a presence in North America; South America, and other countries.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.